Long Term Discontinuation Of Eltrombopag After Remission In Primary Immune Thrombocytopenia: 8-Year Follow-Up Data From 15 Spanish Centers
BLOOD(2019)
Abstract
Background: Successful discontinuation of eltrombopag in certain immune thrombocytopenia (ITP) patients after complete response has already been demonstrated. However, the frequency of this phenomenon and type of candidate patients are still matter of discussion. Moreover, possibility of long term discontinuation responses is not clearly established.
MoreTranslated text
Key words
primary immune thrombocytopenia,eltrombopag
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined